has the whole industrial chain of R&D, manufacturing, and commercialization. We committed to provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established.
Wu Zhiyuan, Director of Development Research Center of People's Government of Pudong New Area, and His Entourage Visited Mabwell for Research and Guidance
World pioneer! Mabwell's Clinical Trial Application for 9MW3011 Injection - An Innovative Drug Accepted by NMPA
Mabwell and Yuanxin Technology Cooperate to Establish a Comprehensive Innovative Marketing Model
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for 君迈康? (Adalimumab)